Evidence map›Paper›PMID 32189076›Full record

ReviewJournal of neural transmission (Vienna, Austria : 1996)2020

Alleviating pain with delta opioid receptor agonists: evidence from experimental models.

Sophie Berthiaume, Khaled Abdallah, Véronique Blais, Louis Gendron

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of neural transmission (Vienna, Austria : 1996), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Reversing Morphine Induced Tolerance: Insights Into Cetirizine and Green Tea Extract Efficacy.Current therapeutic research, clinical and experimental · 2025
    Article
  3. Review
  4. Article
  5. Review
  6. Targeting sensory neuron GPCRs for peripheral neuropathic pain.Trends in pharmacological sciences · 2023
    Review
  7. Article
  8. Article
  9. Article
  10. Advances in the understanding and treatment of pain and headache.Journal of neural transmission (Vienna, Austria : 1996) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sophie BerthiaumeDépartement de Pharmacologie-Physiologie, Institut de Pharmacologie de Sherbrooke, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Faculté de médecine et des sciences de la santé, Université de Sherbrooke, 3001, 12th Avenue North, Sherbrooke, QC, J1H 5N4, Canada.
Khaled AbdallahDépartement de Pharmacologie-Physiologie, Institut de Pharmacologie de Sherbrooke, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Faculté de médecine et des sciences de la santé, Université de Sherbrooke, 3001, 12th Avenue North, Sherbrooke, QC, J1H 5N4, Canada.
Véronique BlaisDépartement de Pharmacologie-Physiologie, Institut de Pharmacologie de Sherbrooke, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Faculté de médecine et des sciences de la santé, Université de Sherbrooke, 3001, 12th Avenue North, Sherbrooke, QC, J1H 5N4, Canada.
Louis GendronDépartement de Pharmacologie-Physiologie, Institut de Pharmacologie de Sherbrooke, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Faculté de médecine et des sciences de la santé, Université de Sherbrooke, 3001, 12th Avenue North, Sherbrooke, QC, J1H 5N4, Canada. Louis.Gendron@USherbrooke.ca.ORCID http://orcid.org/0000-0002-2058-8863
Université de Sherbrooke · CA

Funding

CIHR MOP-136871CIHR PJT-162103
6 · The paper itself

Abstract

The use of opioids for the relief of pain and headache disorders has been studied for years. Nowadays, particularly because of its ability to produce analgesia in various pain models, delta opioid receptor (DOPr) emerges as a promising target for the development of new pain therapies. Indeed, their potential to avoid the unwanted effects commonly observed with clinically used opioids acting at the mu opioid receptor (MOPr) suggests that DOPr agonists could be a therapeutic option. In this review, we discuss the use of opioids in the management of pain in addition to describing the evidence of the analgesic potency of DOPr agonists in animal models.

Indexed as

Acute PainCancer PainChronic PainMigraine DisordersNeuralgiaReceptors, Opioid, deltaAnalgesics, OpioidAnimalsHumansAnalgesics, OpioidReceptors, Opioid, deltaDelta opioid receptorG protein-coupled receptorsPainPrimary afferentsTrafficking

Identifiers

PMID32189076
OpenAlexW3011224348

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.